SCHEMBL10577482

SCHEMBL10577482

CCCCOCCOC(=O)CCS

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.55
DNM1 Q05193 1/20 0.46
TSHR P16473 2/20 0.42
NAAA Q02083 1/20 0.41
CYP3A4 P08684 1/20 0.41
HTR2C P28335 1/20 0.41
EPHX2 P34913 1/20 0.41
ALDH1A1 P00352 2/20 0.41
RARB P10826 1/20 0.40
ATM Q13315 1/20 0.38
MEN1 O00255 1/20 0.38
THRB P10828 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPT P10636 1/20 0.38
PAM P19021 2/20 0.38
LMNA P02545 1/20 0.38
MGLL Q99685 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10578573 0.98 DGKA (0.53) DGKADNM1TSHRNAAACYP3A4
SCHEMBL29797095 0.93 DGKA (0.61) DGKADNM1TSHRNAAAHTR2C
SCHEMBL31121693 0.91 DGKA (0.58) DGKADNM1TSHRNAAACYP3A4
SCHEMBL18179722 0.89 DGKA (0.48) DGKADNM1TSHRNAAAHTR2C
SCHEMBL157557 0.88 DGKA (0.57) DGKADNM1TSHRNAAAHTR2C
SCHEMBL1302517 0.88 DGKA (0.63) DGKADNM1TSHRNAAACYP3A4
SCHEMBL17375071 0.88 DGKA (0.63) DGKADNM1TSHRNAAACYP3A4
SCHEMBL16837163 0.88 DGKA (0.63) DGKADNM1TSHRNAAACYP3A4
SCHEMBL23349392 0.86 DGKA (0.41) DGKADNM1TSHRHTR2CEPHX2
SCHEMBL10579418 0.86 DGKA (0.55) DGKADNM1TSHRNAAAHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218799-A1 BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT AQUARIAN CREDIT FUNDING LLC 2023-07-13 US disclosed
US-20180050129-A1 BIOCOMPATIBLE HYDROGEL POLYMER MATRIX FOR DELIVERY OF CELLS THERAGENICS CORPORATION 2018-02-22 US disclosed
US-20130116341-A1 IN-VIVO GELLING PHARMACEUTICAL PRE-FORMULATION MEDICUS BIOSCIENCES, LLC (US) 2013-05-09 US disclosed
US-4873351-A REACTING ANTIMONY TRIOXIDE WITH ORGANIC MERCAPTAN IN THE PRESENCE OF A LOWER ALIPHATIC CARBOXYLIC ACID SAKAI CHEMICAL INDUSTRY CO., LTD. (JP) 1989-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218799-A1 BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT ALDH1A2, RB1, UACA DGKA 3244/4885DNM1 2026/4885TSHR 1883/4885
US-20180050129-A1 BIOCOMPATIBLE HYDROGEL POLYMER MATRIX FOR DELIVERY OF CELLS CD44, MMP1, ILK DGKA 3848/4885DNM1 1752/4885TSHR 4136/4885
US-20130116341-A1 IN-VIVO GELLING PHARMACEUTICAL PRE-FORMULATION FURIN, ARFGAP1, MGST1 DGKA 2617/4885DNM1 1950/4885TSHR 4254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.